Načítá se...

Directed Evolution of AAV Serotype 5 for Increased Hepatocyte Transduction and Retained Low Humoral Seroreactivity

Most recombinant adeno-associated virus (AAV) capsids utilized in liver gene therapy have significant levels of pre-existing neutralizing antibodies in the human population. These neutralizing factors limit the patient pools eligible for receiving AAV-mediated therapies. AAV serotype 5 (AAV5) does n...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Mol Ther Methods Clin Dev
Hlavní autoři: Qian, Randolph, Xiao, Bin, Li, Juan, Xiao, Xiao
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Gene & Cell Therapy 2020
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7773954/
https://ncbi.nlm.nih.gov/pubmed/33426144
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omtm.2020.10.010
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!